T Matsumoto1, T Inokuma, Y Imai. Show Affiliations » 1. Department of Gastroenterology, Kobe City Medical Center General Hospital, Kobe, Japan.
Abstract
Entities: Chemical Disease
Mesh： See more » 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic useAged, 80 and overAmoxicillin/therapeutic useAnti-Bacterial Agents/therapeutic useClarithromycin/therapeutic useColonic Neoplasms/diagnosisColonic Neoplasms/drug therapyColonic Neoplasms/microbiologyColonoscopyDrug Therapy, CombinationEndoscopy, GastrointestinalEndosonographyFemaleHelicobacter Infections/diagnosisHelicobacter Infections/drug therapyHelicobacter Infections/microbiologyHelicobacter pylori/pathogenicityHumansIntestinal Mucosa/drug effectsIntestinal Mucosa/pathologyLansoprazoleLevofloxacinLymphoma, B-Cell, Marginal Zone/diagnosisLymphoma, B-Cell, Marginal Zone/drug therapyLymphoma, B-Cell, Marginal Zone/microbiologyMultimodal ImagingOccult BloodOfloxacin/therapeutic usePolymerase Chain ReactionPositron-Emission TomographyTomography, X-Ray Computed
Substances： See more » 2-PyridinylmethylsulfinylbenzimidazolesAnti-Bacterial AgentsLansoprazoleLevofloxacinAmoxicillinOfloxacinClarithromycin
Year: 2013 PMID： 23527757 DOI： 10.1111/jgh.12130
Source DB: PubMed Journal: J Gastroenterol Hepatol ISSN： 0815-9319 Impact factor: 4.029